February 20, 2024
The University of Cincinnati Cancer Center is the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.
October 16, 2023
A collaborative team led by University of Cincinnati, University of North Carolina and Duke University researchers is studying how specific cancers and treatments affect patients' risk of stroke.
January 9, 2024
A new trial at the University of Cincinnati Gardner Neuroscience Institute, funded by a $660,000 National Institutes of Health (NIH) grant, will test an at-home tongue endurance exercise to improve patients’ swallowing function after a stroke.
October 17, 2023
The University of Cincinnati Cancer Center has joined the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network (ETCTN), providing patients with access to cutting edge treatments only available through the network.
February 19, 2024
Local 12 and the Cincinnati Business Courier highlighted the University of Cincinnati Cancer Center's Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, opening this summer.
April 4, 2024
Clinical research conducted at the University of Cincinnati College of Medicine and UC Health played a role in the U.S. Food and Drug Administration's March 26 approval of WINREVAIR™ (sotatercept-csrk) for the treatment of pulmonary arterial hypertension (PAH) in adults.
January 11, 2021
COVID-19 vaccine providers across Ohio will soon get better guidance about the next steps for getting shots into arms. Brett Kissela, MD, spoke to WLWT-TV, Channel 5 and said the benefits of the vaccine outweigh any potential side effects.
January 21, 2021
UC research, published in JAMA Oncology, shows that chemotherapy before surgery for some pancreatic cancer patients may not improve survival rates.
September 22, 2020
Drugs.com covers UC research looking at mortality in patients with cancer and COVID-19.
October 20, 2022
New research out of the University of Cincinnati shows that a course of a hepatitis B vaccine provides complete protection for people with HIV. The UC research shows that a three-dose course of the hepatitis B vaccine HEPLISAV-B provides complete protection for people living with HIV who have never been vaccinated against or exposed to the hepatitis B virus (HBV).